New Era of ADME and Beyond (NE-ADME 2026)
June 10, 2026 at MODERNA
325 Binney St., Cambridge, MA 02142
 |
Plenary LectureAmit Kalgutkar, PhDSenior Research Fellow, Rare Diseases & Antivirals Therapeutic Areas DMPK Portfolio Lead at Pfizer Case Studies on Metabolism-Guided Drug Design |
 |
Alison Betts, PhDGlobal Head of DMPK & Modeling @ Takeda Beyond Animals: Human-Based NAMs Driving the Next Era of Biologics Translation |
||
 |
Nikhil Pillai, PhDSenior Principal Scientist, Sanofi From Chemical Structure to In Vivo Pharmacokinetic Profiles: Machine Learning-Enabled Early Drug Discovery |
 |
Bjoern Olav Hald, PhDSenior Scientist II - Drug Metabolism, Novo Nordisk Overcoming the Translational Gap in Peptide Drug Development: Integrating MPS Systems with QSP Modeling |
||
 |
Xiaohua Zhu, PhDSenior Director, DMPK at Nimbus Therapeutics Optimizing ADME/DMPK Strategy to Accelerate Drug Discovery |
 |
Christina Fu, PhDSenior Principal Scientist, Pfizer Immunogenicity Risk Assessment: Enabling Quality by Design in Therapeutic Protein Discovery and Development |
||
 |
Vaibhav Maheshwari, PhDAssociate Director, EMD Serono Quantitative Translational Pharmacology of PROTAC's and Opportunities for Model-Informed Paradigms in R&D |
 |
Stefanus Steyn, PhDResearch Fellow, Pfizer Addressing PROTAC Plasma Protein Binding Challenges |
||
 |
Erik Willems, PhDDirector of Scientific Operations @ Discovery Life Sciences Hepatocyte Spheroids to Improve Duration of Drug Metabolism In In Vitro Assays
|
 |
Matt Silva, PhDCEO @ EMIT Imaging Cryo-Fluorescence Tomography as a Next-Generation Imaging Tool for DMPK and Translational Safety
|
||
 |
Josh Apgar, PhDVP, Head of QSP Software @ Certara Enabling Scalable and Reproducible QSP Modeling Using Certara IQ |
||||
Session I: AI, In-Silico Tools & Translational In Vitro Models
Session II: In-Vitro ADME & Modeling Approaches
Session III: NAMs, IVIVC Trends & Comparative MPS/Organ-On-Chip Platforms
Session IV: Navigating ADME & Translational Hurdles in the Beyond Rule of 5 Chemical Space